The French artificial intelligence (AI) software developer Avicenna.AI has received clearance in the U.S. and the European Union for its Cina Chest AI software.
Cina Chest, which includes tools for the detection and emergency triage of pulmonary embolism and aortic dissection from CT scans, has received the CE Mark in Europe and 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Cina Chest is part of Avicenna's Cina family of AI tools, which also includes the company's Cina Head software, which also has FDA clearance and the CE Mark.
"Our pulmonary embolism and aortic dissection triage tools are the third and fourth algorithms we've released in less than 12 months, demonstrating our ambition to create AI applications that support detection and triage of emergencies throughout the entire body," said Cyril Di Grandi, co-founder and CEO of Avicenna.AI.
The company was founded in 2018 and is based in La Ciotat, France. It specializes in the development of AI algorithms that can identify acute abnormalities, and Cina Chest is the latest application developed for emergency room radiology.
Di Grandi previously co-founded and sold Olea Medical. The other co-founder of Avicenna is radiologist Dr. Peter Chang.
